Lead Product(s): Conestat alfa
Therapeutic Area: Infections and Infectious Diseases Product Name: Ruconest
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
First patient has been enrolled in an investigator-initiated clinical trial in up to 150 patients for the treatment with RUCONEST® of patients with confirmed COVID-19 infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland.
Lead Product(s): Pritelivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: AiCuris Anti-infective Cures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 12, 2020
The companies are collaborating to develop an Early Access Program for pritelivir, for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.